We recently established a novel assay for specific activity (SA) of cyclin-dependent kinases (CDKs) using small tumor samples ( ‡8 mm 3 ). The aim of this study was to investigate the prognostic significance of CDK1SA
introduction
It is well established that systemic adjuvant therapy for early breast cancer significantly reduces the risk of recurrence and death regardless of nodal status [1, 2] . However, the fact that approximately two-thirds of node-negative patients can survive without recurrence even without adjuvant therapy indicates that adjuvant therapy is administered to many patients who actually do not need it. To avoid unnecessary treatments, we need new and more powerful prognostic indicators [3, 4] .
Recently, molecules involved in cell cycle regulation such as cyclins, cyclin-dependent kinases (CDKs) and CDK inhibitors have been attracting considerable attention as potential prognostic indicators [4] [5] [6] . Cyclin E appears to be the most promising of these molecules. High cyclin E expression detected by western blotting has been shown to be strongly associated with unfavorable prognosis, independent of nodal status [5] . However, it is not easy to reproducibly assay total cyclin E or low molecular weight cyclin E expression by western blotting, which does not seem to be suitable for routine laboratory tests.
We have been focusing on CDKs (CDK1 and 2) and investigating their prognostic significance in breast cancers because CDKs play a pivotal role in cell cycle regulation [7, 8] . The CDK expression levels are almost constant but their activities change markedly according to the cell cycle phase. Thus, it is necessary to measure CDK activity itself to accurately evaluate the role of CDKs in cell proliferation. Recently, we succeeded in developing a system that can assay the specific activity (SA) of CDKs using small tissue samples [9] . The aim of this study was to clarify the prognostic implications of CDKSA in breast cancers. 
patients and methods

assay for CDKSA
The assay of CDKSA consists of analyses of protein expression and kinase activity, as previously described [9] . In brief, lysates of frozen tissues were prepared with a homogenizer and stored at -80°C until use. For expression analysis, the lysate was applied to an ImmobiChip (Sysmex, Kobe, Japan). The target protein was detected by sequential reactions with primary antibodies (anti-CDK1, anti-CDK2 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH); Sysmex, Kobe, Japan), biotinylated secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) and fluorescein-labeled streptavidin (Vector, Burlingame, CA). For kinase activity analysis, the CDK1 or CDK2 molecules in the lysate were first captured in a mini-column coupled with anti-CDK1 or anti-CDK2 antibody. Then an in-column kinase reaction and a fluorescein labeling reaction were performed sequentially, and the final reaction mixture was applied to the ImmobiChip. For quantification of both CDK expression and activity, catalytically active recombinant CDK1 or CDK2 (Upstate Biotechnology, Lake Placid, NY) was used as a standard. The CDKSAs were then calculated as kinase activity (U/lL lysate, where 1 U is equivalent to the activity of 1 ng of standard) divided by its corresponding expression (ng/lL lysate). The cut-off values for CDK1SA, CDK2SA and CDK2SA/CDK1SA ratio were defined as the points that gave the best discrimination in RFS. The optimal cut-off points were 100 U/ng for CDK1SA, 800 U/ng for CDK2SA and 5.6 for CDK2SA/ CDK1SA. The distribution of breast tumors according to CDK1SA and CDK2SA is shown in Figure 1 .
assay for human epidermal growth factor receptor type 2 expression HER2 expression was examined by HercepTest (DakoCytomation, Carpinteria, CA) in 195 patients and by western blotting in 87 patients whose primary tissues were not available for HercepTest. The insoluble membrane fraction of the lysate for CDKSA assay was solubilized by RIPA buffer-supplemented protease inhibitor cocktail (SIGMA-Aldrich, St Louis, MO). The resultant supernatant was electrophoresed followed by transfer to PVDF membrane. After blocking, the membrane was treated with polyclonal anti-HER2 antibody (Upstate Biotechnology, Lake Placid, NY), biotinylated anti-rabbit antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and Alexa-Fluor488-streptavidin (Molecular Probes, Eugene, OR). Fluorescent signal intensities of HER2 were measured and normalized to GAPDH expression. HER2 expression was classified as negative, 1+ or 2+. A high concordance (82%) between score 3+ of HercepTest and 2+ of the western blotting was confirmed (data not shown), and both were defined as HER2-positive.
statistical methods
RFS was calculated with the Kaplan-Meier method, and the differences were assessed with the log-rank test. The Cox proportional hazards model was used for both univariate and multivariate analyses. Test results were considered significant for P £ 0.05.
results relationship of various clinicopathologic parameters or CDK1/2SA with prognosis
The relationship of various clinicopathologic parameters with 5yRFS is shown in Table 1 . Lymph node metastases, high histologic grade, estrogen receptor (ER) negativity, progesterone receptor (PR) negativity and HER2 positivity were significantly associated with poor 5yRFS. With respect to Figure 1 . Distribution of breast tumors according to CDK1SA and CDK2SA. Tumors (n = 284) are plotted in two dimensions (logarithmic scales) according to CDK1SA and CDK2SA. Area A includes tumors with high CDK1SA (>100 U/ng) and/or high CDK2SA (>800 U/ng) (n = 37). Area C includes tumors where both CDK1SA and CDK2SA are less than lower measurement limits (n = 33). The remaining tumors are divided into two groups (B1 [n = 85] and B2 [n = 129]) according to the CDK2SA to CDK1SA ratio, with a cut-off at 5.6. Tumors in areas A and B1 are considered to be high-risk for relapse (CDK-based high-risk group) and those in areas B2 and C to be low-risk (CDK-based low-risk group). Tumor without relapse; d, tumor with relapse; .
CDKSAs, patients with high CDK1SA and high-CDK2SA tumors showed a significantly lower 5yRFS than those with low CDK1SA and low-CDK2SA tumors, respectively. Moreover, patients with tumors with a high CDK2SA/CDK1SA ratio showed a significantly lower 5yRFS than those with tumors with a low CDK2SA/CDK1SA ratio.
Next, we studied the relationship of the combination of CDK1SA and CDK2SA with prognosis. Patients with high CDK1SA and/or high-CDK2SA tumors (area A in Figure 1) showed a poor prognosis (5yRFS rate 60%), whereas patients with tumors where both CDK1SA and CDK2SA were less than lower measurement limits (area C in Figure 1 ) were unlikely to develop recurrent diseases (5yRFS rate 96%). The remaining patients were able to be divided into the high-and low-risk groups according to the CKD2SA/CDK1SA ratio; that is, patients with tumors with a high CKD2SA/CDK1SA ratio (area B1 in Figure 1) were at high risk of relapse (5yRFS rate 73%) and those with a low CKD2SA/CDK1SA ratio (area B2 in Figure 1) were at low risk of relapse (5yRFS rate 91%). Accordingly, using the combination of CDK1SA and CDK2SA, all patients could be classified into a CDK-based low-risk group (area B2 and C in Figure 1 ) and a CDK-based high-risk group (area A and B1 in Figure 1) . Patients in the CDK-based high-risk group showed a significantly lower 5yRFS than those in the CDK-based low-risk group (Table 1 and Figure 2A) .
The prognostic impacts of various markers were evaluated by univariate and multivariate analyses ( Table 2 ). In the univariate analysis, lymph node status, histologic grade, ER, PR, HER2 and CDK-based risk were significantly associated with relapse. In the multivariate analysis, however, only lymph node status and CDK-based risk had a significant correlation with relapse (hazard ratio 2.22 and 3.09, respectively).
CDK1/2SA and clinicopathologic parameters. The relationship of CDK-based risk with clinicopathologic parameters was evaluated with the chi-square test. CDK-based high risk showed a significant association with large tumor size (P = 0.035), lymph node involvement (P = 0.046), high histologic grade (P = 0.0008) and PR negativity (P = 0.004), but no significant association with ER (P = 0.362) and HER2 status (P = 0.118).
CDK1/2SA and prognosis according to nodal status. In both node-negative and node-positive subsets, patients in the CDK-based high-risk group showed a significantly lower 5yRFS than those in the CDK-based low-risk group (node-negative, 72.6% vs 97.8%; node-positive, 61.0% vs 79.0%) ( Figure 2B and 2C) .
In the node-positive group, univariate analysis showed that the number of metastatic lymph nodes, ER status and CDK-based risk were significantly associated with relapse, whereas multivariate analysis showed only that the number of metastatic lymph nodes and ER status were significant prognostic indicators for relapse (data not shown). In the node-negative group, univariate analysis showed that the CDK-based risk had a significant association with relapse, and that the histologic grade and PR status had a tendency to be associated with relapse. The multivariate analysis demonstrated that only CDK-based risk is a significant independent prognostic indicator (hazard ratio 6.73).
prognostic factors for node-negative patients receiving hormonal therapy alone Of 178 node-negative patients, 139 (78%) patients received hormone therapy alone as adjuvant therapy, and 14 of these 139 patients developed recurrences. Neither histologic grade nor the St Gallen's criteria [10] , widely used as the risk classification especially for node-negative patients, showed a significant association with relapse in these 139 patients ( Figure 2D and 2E) . However, patients in the CDK-based high-risk group showed a significantly lower . CDK-based low-risk group was composed of patients with tumors showing both CDK1SA and CDK2SA less than lower measurement limits (area C in Figure 1 ) and those with a low ratio of CKD2SA/CDK1SA (area B2 in Figure 1 ). The CDK-based high-risk group was composed of patients with tumors showing high CDK1SA and/or high CDK2SA (area A in Figure 1 ) and those with a high ratio of CKD2SA/CDK1SA (area B1 in Figure 1 ). HER2, Human Epidermal Growth Factor Receptor Type 2.
original article Annals of Oncology 5yRFS than those in the CDK-based low-risk group (74.9% vs 98.4%, P = 0.0001) ( Figure 2F ).
discussion
In this study, we applied our novel assay system to breast cancers to find out whether determination of CDK1SA and CDK2SA could be useful for the prediction of patient outcomes. Although a high CDK1SA, a high CDK2SA and a high CDK2SA/CDK1SA ratio were significantly associated with a poor prognosis, the combination of these parameters (the CDK-based risk) has been found to predict patients' outcomes more accurately than each parameter alone. Multivariate analysis demonstrated that CDK-based risk was a significant prognostic indicator. More importantly, CDKbased risk was a highly significant and independent prognostic indicator for node-negative breast cancers. The strength of this new indicator, CDK-based risk, is that it classified as many as 61% (109/178) of node-negative patients into the low-risk group where the RFS is extremely good, and the remaining 39% (69/178) into the high-risk group where the RFS is so low as to be equivalent to that seen in patients with one lymph node involvement [11] . This excellent capability for differentiation of the CDK-based risk sharply contrasts with that of St Gallen's risk classification of node-negative breast cancers. The latter categorized only 5% (8/166) of our subjects into the low-risk group, where recurrence was observed in 13% (1/8), and the remaining Relapse-free survival (RFS) rates according to the CDK-based risk and St Gallen's risk categorization. In (A) all, (B) node-positive and (C) nodenegative patients, CDK-based high risk was strongly associated with poor prognosis compared to CDK-based low risk. In node-negative patients receiving hormone therapy alone as systemic adjuvant therapy, risk classification according to (D) St. Gallen risk category (2005 version) and (E) histologic grade failed to show a significant difference in RFS. (F) CDK-based risk was able to classify these patients into the high-and the low-risk groups, and their 5-year RFS rates were 74.9% vs 98.4%, respectively (P = 0.0001).
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